Fraunhofer IGB: Third place for Retina-on-a-chip project at the Science2Start competition

On July 30, 2018, Posted by , In News, By , , With Comments Off on Fraunhofer IGB: Third place for Retina-on-a-chip project at the Science2Start competition

At the annual Science2Start competition organized by BioRegio STERN Management GmbH, Dr. Ing. Christopher Probst, scientist in the Organ-on-a-Chip group of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, reached place 3 with the Retina-on-a-Chip project. With “Retina-on-a-Chip”, scientists at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB…

Heidelberg University Hospital/ HITS/ ZMBH: The need for speed – Why malaria parasites are faster than human immune cells

On July 23, 2018, Posted by , In News, By , With Comments Off on Heidelberg University Hospital/ HITS/ ZMBH: The need for speed – Why malaria parasites are faster than human immune cells

Elementary cytoskeleton protein is different in parasites and represents a starting point for a possible new therapy against malaria infections. Researchers from the Heidelberg University Hospital, the Centre for Molecular Biology at the University of Heidelberg (ZMBH), and the Heidelberg Institute for Theoretical Studies (HITS) have published these findings in…

EMBL scientists show that mammalian life begins differently than we thought

On July 16, 2018, Posted by , In News, By , , With Comments Off on EMBL scientists show that mammalian life begins differently than we thought

It was long thought that during an embryo’s first cell division, one spindle is responsible for segregating the embryo’s chromosomes into two cells. EMBL scientists now show that in mice, there are actually two spindles, one for each set of parental chromosomes, meaning that the genetic information from each parent…

HITS: New computational method for drug discovery

On July 12, 2018, Posted by , In News, By , , With Comments Off on HITS: New computational method for drug discovery

HITS researchers developed tauRAMD, a tool to predict drug-target residence times from short simulations. The method is illustrated on the cover page of July 2018 issue of the Journal of Chemical Theory and Computation, software is freely available. The graphical image used for the cover of the JCTC . Image:…

DKFZ: Mechanism of action of a diabetes drug differs between males and females

On July 11, 2018, Posted by , In News, By , , With Comments Off on DKFZ: Mechanism of action of a diabetes drug differs between males and females

Most diabetes medications do not attack the cause of the disease. Glitazones are different: they improve insulin sensitivity and can promote the conversion of unhealthy white adipose tissue into fat-burning beige adipocytes. However, due to their side effects, they are hardly used. Scientists from the German Cancer Research Center are…

DKFZ: Brain cancer – Typical mutation in cancer cells stifles immune response

On July 11, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: Brain cancer – Typical mutation in cancer cells stifles immune response

The exchange of a single amino acid building block in a metabolic enzyme can lead to cancer. In addition, it can impair the immune system, scientists from the German Cancer Research Center (DKFZ), the University Hospitals in Mannheim and Heidelberg, and the German Cancer Consortium now report. It thus blocks…

Boehringer Ingelheim Championing Early-Stage Life Science Entrepreneur Innovation in Heidelberg

On July 10, 2018, Posted by , In Press Releases, By ,, , With Comments Off on Boehringer Ingelheim Championing Early-Stage Life Science Entrepreneur Innovation in Heidelberg

Heidelberg 10.07.2018 BioRN as cross-cutting representative of the life science community supported Boehringer Ingelheim in the organisation, promotion and execution of this successful event. Open panel discussion during the Summer Networking Reception. Partnerships with early-stage companies often spark some of the most innovative research and development collaborations in the healthcare…

DKFZ/Heidelberg University: New therapy makes blood cancer cells visible for the immune system

On June 27, 2018, Posted by , In News, By , , With Comments Off on DKFZ/Heidelberg University: New therapy makes blood cancer cells visible for the immune system

Chronic lymphocytic leukemia (CLL) is the most common type of blood cancer in adults. It can be treated with chemotherapy and oral drugs but this treatment cannot cure the cancer completely. Although the human immune system is capable of fighting the cancer cells, it often fails to notice them early…

DKFZ: 14 new breast cancer risk genes discovered

On June 26, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: 14 new breast cancer risk genes discovered

Many genetic markers associated with the familial breast cancer risk are outside the protein-coding regions of the genome and are likely to regulate the activity of neighboring genes. In a large international network, in which numerous DKFZ researchers were also involved, scientists have now combined genome-wide association studies with an…

EMBL: Miniature testing of drug pairs on tumour biopsies

On June 25, 2018, Posted by , In News, By ,, , With Comments Off on EMBL: Miniature testing of drug pairs on tumour biopsies

Microfluidic device in the Merten lab. IMAGE – Ramesh Utharala, EMBL Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised…